

Speakers

Prof. Dr. Francis Ayuketang Ayuk, UKE Hamburg

Prof. Dr. Christian Chabannon, Aix-Marseille Universität, Frankreich

Prof. Dr. Klaus Cichutek, Paul-Ehrlich-Institut, Langen

Prof. Dr. Hermann Einsele, Universitätsklinikum Würzburg

Prof. Stephen Gottschalk, St. Jude Hospital, Memphis, USA

PD Dr. Uta Höpken, MDC Max-Delbrück-Centrum, Berlin

Prof. Dr. Manel Juan, SJD Barcelona Children's Hospital, Spanien

Prof. em. Dr. Hans-Jochem Kolb, München

Dr. Armin Rehm, MDC Max-Delbrück-Centrum, Berlin

Dr. Christoph Stein-Thörlinger, DKFZ, Heidelberg

Prof. Dr. Marion Subklewe, LMU München

PD Dr. Simone Thomas, Universitätsklinikum Regensburg

Dr. Eva-Maria Wagner-Drouet, Universitätsmedizin Mainz

Prof. Dr. Andreas Kulozik, PhD, Pädiatrische Onkologie, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Heidelberg

Dr. Patrick Derigs
PD Dr. Sascha Dietrich
Prof. Dr. Peter Dreger
Prof. Dr. Dr. Thomas Luft, PhD
Prof. Dr. Carsten Müller-Tidow
Dr. Tim Sauer
Dr. Maria-Luisa Schubert
PD Dr. Anita Schmitt
Prof. Dr. Michael Schmitt
Medizinische Klinik V (Hämatologie, Onkologie und Rheumatologie), Universitätsklinikum Heidelberg

Sponsors

GILEAD Sciences GmbH
Novartis Pharma GmbH
Celgene GmbH
bluebird bio (Germany) GmbH
Cellgenix GmbH
Clinigen Healthcare Germany
Miltenyi Biotec GmbH
MSD Sharp & Dohme GmbH
Takeda Pharma Vertrieb GmbH & Co. KG
Roche Pharma AG
Hexal AG
Janssen-Cilag GmbH
Mallinckrodt Pharmaceuticals (Therakos (UK) Ltd)
FUJIFILM Irvine Scientific, NL

Virtual conference accessible through cell-therapy-symposium.ukhd.de

Contact:

Universitätsklinikum Heidelberg
Medizinische Klinik V, Zelluläre Immuntherapie
Im Neuenheimer Feld 410, 69120 Heidelberg

Contact person: Regina Hollenbach
Tel.: 06221 56-7989
E-Mail: Regina.Hollenbach@med.uni-heidelberg.de

Venue

Medical Clinic
Im Neuenheimer Feld 410
69120 Heidelberg



Approach by car

A656 direction Heidelberg, continue on B37 direction University Hospital / Neuenheimer Feld. After crossing the Neckar at the first traffic light left. into the Jahnstraße, then turn right into the street "Im Neuenheimer Feld". To the Medical Clinic after approx. 100 meters li. in the Kirchnerstraße and at Leit- und Informationszentrale 2 (LIZ) pass the barrier. After approx. 400 m the street name changes to "Hofmeisterweg"; After approx. 300 m, the medical clinic is on the right. Opposite is the parking garage P160, a few meters further the zoo parking garage.

Approach by public transport

Tram lines 21 and 24:
> Berliner Straße, stop "Jahnstraße"> Change to bus line 32> Bus stop is located in Jahnstraße
> Berliner Straße, stop "Technologiepark"> change to bus line 31

Bus lines 31 and 32:
Stop "Medical Clinic": The bus stop is located directly in front of the main entrance to the clinic.



UNIVERSITÄTS
KLINIKUM
HEIDELBERG



4th CELL THERAPY SYMPOSIUM

November 6 & 7, 2020

Medical Clinic, Grand Auditorium
Im Neuenheimer Feld 410
69120 Heidelberg

Department of Medicine V (Hematology,
Oncology and Rheumatology)



Dear colleagues,

Since our last Cell Therapy Symposium only one year has elapsed. Within this short period of time, tremendous progress has been made in our clinic regarding CAR T cells therapy: more than 70 patients have received this innovative treatment at our center. In Europe more than 700 patients have been treated for acute leukemia, Non-Hodgkin lymphoma and myeloma with remarkable success. Therefore the therapeutic algorithms for the treatment of these diseases need to be revisited. Moreover, the safe management of cytokine release syndrome, neurotoxicity and prolonged cytopenia will be highlighted in this symposium. In addition, novel targets and preclinical research for further development of immunogene therapy will be discussed.

We are very proud to present a panel of speakers from the major CAR T cell centers in Germany, France and Spain to give an update of the current status. Also, we are very excited that we could win Prof. Gottschalk, St. Jude Hospital, Memphis/USA to give a key note lecture on his impressive achievements in the field of immuno cell therapy.

We are looking forward to welcoming you to our symposium.

With very warm regards from Heidelberg



Michael Schmitt Carsten Müller-Tidow Peter Dreger

The participation is free of charge.

The meeting has been certified from the Landesärztekammer and CME points are granted.

To ensure proper organization, we would welcome your registration through cell-therapy-symposium.ukhd.de at latest October 15th, 2020.

Program – Day 1

12:00	Registration
13:00	Welcome address Carsten Müller-Tidow
	Chairs: Carsten Müller-Tidow / Peter Dreger
13:10	Current Status report of the Heidelberg HD-CAR-1-Trial Michael Schmitt
13:30	2 years of experience with commercial CARTs in Heidelberg: Lessons to be learned Peter Dreger
13:50	CD70 and CD96 as novel targets for CAR T cell therapy in myeloid disease Tim Sauer
14:10	Transposon driven CAR T cell therapy Hermann Einsele
14:30	BCMA-CAR production in a closed system Armin Rehm
14:50	From DLIs to allo-CARs Hans-Jochem Kolb
15:10	Coffee break
	Chairs: Anthony D. Ho / Andreas Kulozik
15:40	Practical side effect management in CAR-T cell therapy Maria-Luisa Schubert
16:00	EBMT Registry for CAR T cells Christian Chabannon
16:20	Leukapheresis for CARs – what is important for the proper preparation of the patient? Anita Schmitt

16:40	Regulatory issues with genomic editing Klaus Cichutek
17:00	Gene therapy for thalassemia patients Andreas Kulozik
17:20	KEY NOTE: CAR T-cell therapy for solid tumors: bright future or dark reality? Stephen Gottschalk

Program - Day 2

	Chairs: Eva-Maria Wagner-Drouet/Marion Subklewe
09:00	CMV reactivation after transplantation of stem cells or CARs Patrick Derigs
09:10	Home care setting for foscavir application E. Wagner-Drouet
09:30	Experience with home-brewn CARs in Barcelona Manel Juan
09:50	Pathophysiology of neurotoxicity CAR-T cell therapy Marion Subklewe
10:10	Finetuning CD19 CART indications – conclusions from prognostic factor analyses Francis Ayuk
10:30	Novel CAR constructs for multiple myeloma Uta Höpken
10:50	Coffee break
11:20	Chairs: Anita Schmitt / Tim Sauer
	Endothelial biomarkers and CART toxicity Thomas Luft
11:40	Impact of CARs on the microbiome Christoph Stein-Thöringer
12:00	Lymphoma relapse after CARs – strategies for prevention and treatment? Sascha Dietrich
12:20	PRAME-TCR therapy of patients with AML/MDS or myeloma Simone Thomas
12:40	Summary Michael Schmitt